Hirsutism is androgen-dependent excessive terminal hair growth in a male pattern that commonly appears in women. Many drugs, including dehydroepiandrosterone sulfate, testosterone, danazol, and anabolic steroids, can also induce hirsutism because of their inherent androgenic effects; however, the association between antiestrogenic drugs, used during the course of breast cancer treatment, and hirsutism is not established. Herein, we report a rare case of hirsutism following adjuvant antiestrogen therapy in a patient with breast cancer. A 51-year-old woman presented with facial hirsutism since 3 months. A year ago, she had undergone surgery and chemotherapy for breast cancer. Antiestrogenic drugs, tamoxifen and goserelin, were subsequently administered to prevent the recurrence of the cancer. Two weeks later, she developed hirsutism limited to the face. Physical examination showed increased hair thickness and density on both sideburns. In addition, diffuse hair loss was also observed on the scalp. She had no relevant history of other systemic illness or medication affecting hair growth. Laboratory findings were within normal limits. The pattern of terminal hair growth on the skin following administration of the drugs and the exclusion of other causes suggested antiestrogenic drug-induced hirsutism. She underwent chemical depilation with potassium thioglycolate cream, and this treatment was cosmetically acceptable with no side effects.